Bristol Myers Squibb has linked its CD19-directed CAR-T cell therapy to sustained clinical responses in people with systemic ...

Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this ...

Prabhu tells PEOPLE exclusively that she asked the show’s directors to be replaced due to her condition, but ultimately ...

Q2 2024 Earnings Call Transcript November 12, 2024 Operator: Good day and thank you for standing by. Welcome to the Roivant ...

--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune ...

Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by ...

1 patient experienced a dose-limiting toxicity of grade 3 myositis/myasthenia gravis. In addition, immune-related adverse events that necessitated treatment with high-dose steroids were reported in 6 ...

Katie Tinkler is one of three patients who has received CAR T-cell therapy with the hope of remission and the chance to ditch lifelong drugs.

To evaluate the influence of environmental factors and prematurity relating to juvenile dermatomyositis (JDM), its course and refractoriness to treatment. Maternal exposure to occupational pollutants ...

Batoclimab data coming next year in MG, CIDP and TED and brepocitinib in dermatomyositis top line data coming in ... We really only had one additional subject in each dose arm of the treatment failure ...

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.